1. catalystcrusin
2. fullerfamily03
3. purpledeedee247
4. txrdr46
5. videoGURU
1.videoGURU 01/25/2018
Biogen reported Q4 Spinraza sales +34% Q/Q to $363 mln, above estimates (Biogen markets the drug for Ionis)
2.purpledeedee247 05/11/2018
Confirms FDA Advisory Committee
3.fullerfamily03 04/10/2018
Company has licensed IONIS-AZ6-2.5-LRx to AstraZeneca following advancement of the drug into development
4.catalystcrusin 10/17/2017
They need to pound the table on this.... Akcea Presents Data Demonstrating Significant Burden of Illness in Familial Chylomicronemia Syndrome {Link}
5.catalystcrusin 04/19/2018
Presentations at the 2018 American Academy of Neurology Highlight the Broad Potential of Antisense Drugs for Neurological Diseases
6.fullerfamily03 03/02/2018
IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease
7.purpledeedee247 04/20/2018
Biogen and Ionis expand strategic collaboration to develop drug candidates for a broad range of neurological…
8.fullerfamily03 04/24/2018
Biogen reported Q1 Spinraza sales flat Q/Q at $364 mln vs. ests near $380 mln
9.catalystcrusin 03/26/2018
Ionis and Akcea Present New Data from ATTR Amyloidosis Program at 16th International Symposium on Amyloidosis
10.videoGURU 10/17/2017
Can this push higher? Upper $60s?
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW